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Abstract
Background: Children initially hospitalized with severe anaemia in Africa are at high risk of readmission or death
within 6 months after discharge. No intervention strategy specifically protects children during the post-discharge
period. Recent evidence from Malawi shows that 3 months of post-discharge malaria chemoprevention (PMC) with
monthly treatment with artemether-lumefantrine in children with severe malarial anaemia prevented 31% of deaths
and readmissions. While a confirmatory multi-centre trial for PMC with dihydroartemisinin-piperaquine is on going
in Kenya and Uganda, there is a need to design and evaluate an effective delivery strategy for this promising
intervention.
Methods: This is a cluster-randomized trial with 5 arms, each representing a unique PMC delivery strategy.
Convalescent children aged less than 5 years and weighing more than 5 kg admitted with severe anaemia and
clinically stable are included. All eligible children will receive dihydroartemisinin-piperaquine at 2, 6 and 10 weeks
after discharge either: 1) in the community without an SMS reminder; 2) in the community with an SMS reminder;
3) in the community with a community health worker reminder; 4) at the hospital with an SMS reminder; or 5) at
the hospital without an SMS reminder. For community-based strategies (1, 2 and 3), mothers will be given all the
PMC doses at the time of discharge while for hospital-based strategies (4 and 5) mothers will be required to visit
the hospital each month. Each arm will consist of 25 clusters with an average of 3 children per cluster giving
approximately 75 children and will be followed up for 15 weeks. The primary outcome measure is uptake of
complete courses of PMC drugs.
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Discussion: The proposed study will help to identify the most effective, cost-effective, acceptable and feasible
strategy for delivering malaria chemoprevention for post-discharge management of severe anaemia in under-five
children in the Malawian context. This information is important for policy decision in the quest for new strategies
for malaria control in children in similar contexts.
Trial registration: ClinicalTrials.gov: NCT02721420. Protocol registered on 29 March 2016.The study was not
retrospectively registered but there was a delay between date of submission and the date it first became available
on the registry.
Keywords: Children, Severe anaemia, Post-discharge malaria chemoprevention, Malaria, Dihydroartemisinin-
piperaquine, Cluster randomised trial
Background
Severe anaemia is a reduction in haemoglobin (Hb) con-
centration below 5 g/dL or haematocrit below 15%. Glo-
bally, 43% of children have anaemia and in Africa 3.6%
have severe anaemia [1]. Severe anaemia is a leading
cause of hospital admissions contributing substantially
to paediatric mortality in Africa. Hospitalized children
with severe anaemia are particularly at risk within the
first 3 months post-discharge, mostly due to a combin-
ation of environmental, behavioural, nutritional and gen-
etic risk factors [2–6]. A case-control study in Malawian
children indicated that children aged less than 5 years
admitted with severe anaemia were not only at high risk
of dying during the acute phase in-hospital but also for
several months after discharge from the hospital. 17.2%
of children with severe anaemia experienced an all cause
mortality compared to 2% of controls without severe an-
aemia [7].
By 18 months post discharge, 10.2% of children with
severe anaemia were re-admitted with rebound severe
anaemia and 12.6% had died, which is nine times higher
than the mortality in community-based, age matched
children with mild anaemia. High rates of post-discharge
morbidity and mortality have also been reported in west-
ern Kenya and Uganda, where 36.5% of children aged
less than 5 years admitted with severe anaemia died after
18 months of follow up [3, 7].
Previous observational studies in western Kenya and a
recent intervention study in a high transmission areas in
Malawi showed that malaria in the post-discharge period
is an important contributor responsible for a slow haem-
atological recovery, rebound severe anaemia and mor-
bidity [3, 5, 7]. Many children in these areas experience
episodes of new or recrudescent malaria infections after
discharge, which negates the initial rise in haemoglobin
(Hb) achieved by blood transfusion in hospital [3, 8].
Haematological recovery from malaria-associated an-
aemia is known to take at least 6 weeks. This period
may be prolonged in those with persistent or new mal-
aria infections due to on-going red cell destruction and
red blood cell production failure [9].
Standard treatment guidelines for severe anaemia in
many countries in sub-Saharan Africa consists of a blood
transfusion combined with presumptive intravenous
anti-malarial treatment (quinine or artesunate) plus anti-
biotics if bacterial infections are suspected. Once chil-
dren have stabilized and can be switched to oral
treatment, they receive a 3-day treatment course with
artemisinin-based combination therapy (ACT), usually
artemether-lumefantrine (AL). Children are often dis-
charged with a short course of iron and folate, typically
with no scheduled follow-up [8]. Creating a prophylactic
time-window post-transfusion, is suggested to allow time
for the bone marrow to recover, resulting in a more sus-
tained haematological recovery post-discharge. Data
from a previous study in Malawi show that this process
takes 2–3 months in children with severe anaemia [3, 7].
Recently, the use of Intermittent Preventive Treatment
(IPT) in children with severe anaemia during the rainy
season reduced clinical attacks of malaria by more than
80% in areas with highly seasonal transmission [10].
PMC is a version of IPT designed to clear existing infec-
tions and provide prolonged prophylaxis against new
infections.
A study in Malawi showed that provision of 3 months
of chemoprevention with 3 full treatment courses of
artemether-lumefantrine (AL), given in-hospital for
initial malaria episode and at 1 and 2 months
post-discharge, prevented 41% of deaths or readmissions
due to severe anaemia or severe malaria during a
6 months follow-up period [2, 7, 11, 12]. These results
are consistent with studies of children with severe an-
aemia in Gambia, who received chemoprevention given
as monthly intermittent preventive therapy with SP or as
weekly prophylaxis with pyrimethamine-dapsone tar-
geted during the malaria transmission season [12]. For
these children, the rate of clinical malaria was halved
and all-cause hospital readmission was reduced by 78%
in one trial, and recurrence of severe anaemia was re-
duced by 78% in the other [12–14]. These data indicate
that IPT in the post-discharge period may potentially
provide substantial health benefits [13].
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Rationale
In the past two decades, most research on severe anaemia
and severe malaria have focused on reducing in-hospital
mortality. A major and potentially preventable component
of the disease burden occurs after discharge from hospital
and a proactive approach using PMC could offer substan-
tial public health gains [11], and is a priority area for re-
search. There is, however, no specific delivery strategy that
has been scaled up to address this high-risk post-discharge
period. Despite being a relatively simple intervention, the
implementation of PMC in African settings may face chal-
lenges due to weak healthcare systems that are unique in
different contexts. PMC requires appropriately designed
delivery strategies because treatment must be adminis-
tered for 3 days at different pre-specified intervals
post-discharge.
Delivery of PMC to the target population will require
new systems to be established that are sustainable and
cost-effective. In contrast to IPT strategies in infants
(IPTi) and pregnant women (IPTp), which are delivered
through the expanded programme on immunization
(EPI) and antenatal clinics, the delivery strategies for
PMC are not yet in place. Some evidence shows that de-
livery of IPT to children (IPTc) through community
health workers is feasible and well accepted in rural
West Africa [12]. In Malawi, the health system also in-
clude village health volunteers (VHVs) and Health Sur-
veillance Assistants (HSAs) who could deliver PMC or
schedule post-discharge visits to clinics or hospital out-
patient departments for subsequent PMC doses [14].
Since PMC targets a very high-risk group of hospitalized
children who already have contact with the health-care
system, the point of entry is already established [2, 12].
This trial is part of a larger project under the PMC con-
sortium with 5 main activities in Malawi, Kenya and
Uganda that aim to address the gaps in knowledge on
whether PMC should be recommended as a strategy for
the post-discharge management of children with severe
anaemia to the WHO. The PMC trial in Malawi specific-
ally aims to identify the most effective, acceptable and
cost-effective strategy for delivering PMC and if use of
short message service has additional benefits.
Study aims and objectives
The primary objective of the trial is to determine the
optimum PMC delivery strategy by comparing
community-based versus health facility-based strategies in
order to inform policy decision. Specifically we aim to com-
pare PMC uptake (adherence) levels and safety between
community-based versus health facility-based strategies. To
determine and compare health system and family/house-
hold costs of delivering and receiving PMC using the alter-
native proposed strategies. To assess the feasibility and
acceptability of delivering and receiving PMC in a typical
Malawi health system setting. To determine whether SMS
or Health Surveillance Assistant (HSA) reminder has add-
itional benefit on PMC uptake (adherence) levels. To esti-
mate the incremental cost-effectiveness and equity impact
of the alternative delivery strategies.
Methods
Study design
This is a single-centre open label cluster randomized clin-
ical trial with 5-arms. A cluster represents a village, which
is the smallest administrative unit and overseen by a vil-
lage headman. A total of 1387 villages in the catchment
areas of Zomba Central hospital in southern Malawi will
be involved in this study.
Trial drug
The study drug used in this trial is Eurartesim® manu-
factured by Sigma-Tau pharmaceuticals. This is a GMP
certified co-formulated artemisin-based antimalarial
combination, which contains 20 mg Dihydro-Artemesi-
nin and 160 mg Piperaquine. It is administered accord-
ing to body weight 2 (PMC-1), 6 (PMC-2) and
10 weeks (PMC-3) after discharge from hospital, each
course for three consecutive days.
Study participants
Children aged 4 to 59 months admitted to Zomba central
hospital with a diagnosis of severe anaemia either by
haemoglobin of < 5 g/dl or clinically assessed as severely
anaemic but clinically stable and have received all treat-
ments according to the hospital standard of care are
screened for inclusion in the trial at the time of discharge
from hospital. Caretakers of children who meet the eligi-
bility criteria are given general information about the trial
and those who are interested are required to give written
consent for the child to participate into the study.
Interventions
All children receive DHP and hence there are no pla-
cebo arms in this trial. However, children are random-
ized to receive PMC as follows:
Community-based arms
Arm 1
PMC drugs given at discharge without SMS reminder:
The guardian receives all drugs for PMC-1, PMC-2 and
PMC-3. They are instructed on how and when to give
these drugs to the children when being discharged from
hospital. The dates for each course are documented in
the child’s health book.
Arm 2
PMC drugs given at discharge with SMS reminders: The
guardian receives all drugs for PMC-1, PMC-2 and
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PMC-3 and is instructed on how and when to give these
drugs. Additionally they are reminded via SMS to give
the drugs to the child one day before each treatment
course is due.
Arm 3
PMC drugs at discharge with Health Surveillance Assist-
ant (HSA) reminders: The guardian receives all drugs for
PMC-1, PMC-2 and PMC-3 and is instructed on how and
when to give these drugs. Additionally, HSAs which are
part of existing networks of community-based volunteers
taking part in village health committees are reminded via
SMS to go and remind the guardian to give the drugs to
the child one day before each treatment course is due.
Hospital/facility based arms
Arm 4
PMC drugs collected from the hospital: At discharge,
the guardian is instructed to return to the outpatient
department (OPD) of the hospital each month to collect
drugs for PMC-1, PMC-2 and PMC-3. They do not re-
ceive any form of reminder other than what has been
documented in the child’s health card.
Arm 5
PMC drugs at hospital with SMS reminders: At discharge,
the guardian is requested to return to the OPD to collect
drugs for PMC-1, PMC-2 and PMC-3. Additionally they
will be reminded via SMS to come to the clinic to collect
drugs one day before each treatment course is due.
Recruitment and follow up
Figure 1 shows the study flowchart from the standard
protocol items: recommendations for interventional tri-
als (SPIRIT). Every morning, the study staff at Zomba
Central Hospital goes through all newly admitted chil-
dren’s files in order to identify and pre-screen children
who meet the study criteria. During this acute phase of
Fig. 1 Study flowchart adapted from the standard protocol items: recommendations for interventional trials (SPIRIT)
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illness, pre-study screening involves confirming the
study criteria and provision of routine standard of care
treatment. No study specific information or samples are
collected in this point of time. The role of the study
team during pre-study screening is to review the diagno-
sis and ensure that the potential study participants get
the standard quality of care for severe malarial anaemia.
Each pre-screened subject is assigned a pre-screening
number in sequential order regardless of whether they
fulfil the pre-screening eligibility criteria. After the child
has recovered sufficiently, the caretaker is approached
for further screening for eligibility. Caretakers of chil-
dren who fulfil the eligibility criteria and who agree to
participate in the research provide written informed con-
sent before enrolling into the study. The study partici-
pant’s demographic data, relevant clinical information,
including the previous and current medical history, and
laboratory information is collected simultaneously. Fur-
thermore, a physical and clinical examination is performed
and captured on the enrolment case report forms (CRFs).
Randomization and allocation methods
The unit of randomization is villages within the catchment
area of Zomba central hospital. 400 out of the 1387 villages
were randomly selected and randomized to one of the study
arms, where each arm represents a different implementation
alternative. When a child is enrolled and all study proce-
dures have been done, the study data officer enters the name
of the village where the child resides into a pre-programed
database and this automatically generates the study arm and
study identification number. The participants and the study
staff are aware of the study arm assigned. However, the study
statistician who will perform the final analyses will be
blinded to the allocated treatment arm.
Follow up procedures
Table 1 summarises the recruitment and follow up pro-
cedures for the study. Depending on the trial arm to
which the child is allocated, the caretaker is either
scheduled to return to OPD clinic for PMC drugs at
two, six and ten weeks (facility based strategies), or be
given all the courses of drugs at discharge to administer
them at home also at two, six and ten weeks (commu-
nity based strategies). This information is documented
in the child’s health book. All participants, irrespective
of arm, are visited at home shortly after the two, six and
ten scheduled PMC treatments to assess DHP uptake.
These home visits are for adherence assessment, vital
registration and health economic assessments only, and
not for clinical assessment. The PMC follow up period
Table 1 Recruitment and follow-up procedures
Enrolment Allocation Follow up














Arm 1: All PMC drugs given at discharge without monthly SMS reminder X X X
Arm2: all PMC drugs given at discharge with monthly SMS reminder X X X
Arm 3: All PMC drugs given at discharge with HAS reminder. X X X
Arm 4: PMC drugs collected monthly at the OPD with SMS reminder. X X X




Physical examination X X
Blood samples X X
Adverse event assessment X X X X X X
OUTCOMES
Adherence X
Clinical safety X X X X
Cost-effectiveness X
Acceptability and feasibility X
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ends at 15 weeks after enrolment, which is four weeks
after the third scheduled PMC course. Participants are
then requested to come to the clinic 15 weeks after en-
rolment for an end of study assessment. Transport is re-
imbursed for the study end visit. In addition, subject’s
parent or guardian are instructed to return his/her child
to the study clinic for evaluation free of charge at any
time if their condition warrants medical attention during
the 15 weeks follow-up period after discharge.
Data collection and outcome measures
Adherence outcome measures
The primary outcome is the level of uptake of PMC
drugs which will be assessed by unannounced home
visits after each course whereby pill counts will be done.
Hundred percent uptake of PMC drugs will be defined as
administration of all 3-day treatment courses (i.e. 9 doses),
given at 2, 6 and 10 weeks after discharge from hospital.
Sixty percent of PMC drugs are defined as administration
of 6 or more (but less than 9) of the daily dosages out of
the total of 9.30% of PMC drugs will be defined as adminis-
tration of 3 or more (but less than 6) of the daily dosages
out of the total of 9. Less than 30% of PMC drugs is defined
as administration of less than 3 of the daily dosages out of
the total of 9, given 2, 6 and 10 weeks after discharge.
Clinical outcomes
Study instruments include structured forms for clinical
history, physical assessment, laboratory evaluations and
clinical information collected on history of current and
previous illnesses and hospital admissions is collected in
addition to hospitalizations and mortality. For children
who are hospitalized during the follow-up period, data is
collected on the length of hospitalization, diagnosis,
treatments provided, laboratory results, and participant
outcomes. Physical examination and laboratory tests in-
clude: height, weight, mid-upper arm circumference,
malaria rapid test results, blood slide results, parasit-
aemia level, and haemoglobin concentration. This will
be used to assess all-cause mortality, incidence rate of
all-cause hospital readmissions, incidence rate of read-
missions due to severe anaemia (Hb < 5 g/dL) or severe
malaria defined by the administration of parenteral Arte-
sunate or Quinine, incidence rate of non-severe
all-cause sick-child clinic visits, specifically incidence
rate of clinic visit due to RDT/microscopy confirmed
non-severe malaria during the study period.
Cost and economic evaluation outcomes
Information about expenses, resource and time use with
open-ended fields for unanticipated findings and place
for comments will be collected. Demographic informa-
tion on children is collected including age, sex, while re-
ligion, village of residence and socioeconomic features of
their household is also recorded as well as cost informa-
tion for the economic evaluation. This will assess health
provider’s cost of delivering the PMC services, care-
takers’ cost of receiving the PMC services, incremental
cost-effectiveness ratio (ICER) of PMC delivery strategies
and equity impact by socioeconomic status of PMC de-
livery strategies on main and secondary outcomes.
Acceptability and feasibility outcomes
In addition there will be interview guides for in-depth inter-
views and focus group discussions with a selection of care-
takers and health workers who have been involved in the
PMC trial. This information will be used to assess the ac-
ceptability of PMC, adaptations to health workers’ working
practices required to implement PMC, perceptions of
implementing PMC through different delivery strategies,
and recommendations on effective implementation.
Sample size
The sample size calculation has been adjusted for the
design effect using the coefficient of variation method in
order to account for the Intra-cluster Correlations (ICC)
[15, 16]. We assumed that the cluster sizes would be uni-
formly distributed between 2 and 4 children [2, 4]. This
gives a mean cluster size of 3 children per village per year
and a standard deviation of cluster sizes of 0.58. Hence
the coefficient of variation of cluster sizes (CV) is 0.58/3
= 0.19 and CV2 = 0.036. Assuming an intra-cluster correl-
ation coefficient (ICC) of 0.1 and allowing for 10%
loss-to-follow-up, a sample size of 25 clusters (villages) of
an average of 3 children per village (75 children per arm,
N = 375 overall (for 125 clusters for the 5 arms)) has 80%
power to detect a 25% absolute increase in uptake from an
estimated 50% in the OPD and delivery at home groups to
75% in the arms supported by SMS reminders (α = 0.05).
The ICC of 0.1 is slightly more conservative than the ICC
in a previous trial of delivery approaches for IPTc in the
Gambia.
Data management and statistical analysis
Data is collected and recorded by one of the trained
study staff at the point of contact. Data is entered dir-
ectly into computer tablets that will be pre-programmed
and uploaded with electronic case report forms (eCRFs).
The eCRFs have crosschecks for verification, validation
and comply with Good Clinical Practices (GCP). These
gadgets are connected to a desktop allowing data to be
directly uploaded into a database.
The percentage of children receiving PMC according to
schedule in each arm will be obtained and compared be-
tween arms using relative risks (RR) and the 95% CI for the
RR will be reported. The estimates of the RR will be ad-
justed for prognostic factors and potential confounding fac-
tors at baseline using log binomial or Poisson regression
Gondwe et al. BMC Pediatrics  (2018) 18:238 Page 6 of 8
with adjustment for cluster effects. Using Cox regression,
hazard ratios will be calculated for morbidity endpoints
such as incidence of severe anaemia, severe malaria and all
cause hospital re-admissions, for repeated events with ro-
bust standard error estimation methods to account for cor-
relation between episodes within children. Incidence rates
per child-year and absolute rate reductions will also be
calculated.
Discussion
This protocol describes a study in which we will deter-
mine the optimum PMC delivery mechanism in a Mala-
wian context by comparing community versus health
facility based strategies. Presently in African health sys-
tems and particularly in Malawi, post-discharge health
management systems are not in place, and there is need
to assess a number of relevant strategies for effective de-
livery of PMC in a largely rural community that would
typically benefit from this intervention.
We postulate that this post-discharge care in the form
of PMC may be delivered either in the community or at
a health facility. The most likely scenario where the
health care provider is least involved would be where
mothers are given all the PMC drugs on discharge from
hospital and allowed to administer the drugs on her own
to the child (Arm 1). In recent years there has been suc-
cessful disease control programs operationalizing more
decentralized drug delivery programs in the community
in low-income countries, making it a viable option for
PMC. However as we postulate that the mother could
forget to administer the PMC, we would like to test two
different reminder systems. The first is through the
use of SMS technology, which has been shown to be
user-friendly and acceptable from our own pilot work
(unpublished pilot study) and other current programs
in Malawi (Arm 2 and 5).
An alternate reminder system is the use of Health Sur-
veillance Assistants (HSA). HSA are Ministry of Health
(MoH) employees who are responsible for basic health
promotion activities in the community. Ideally MoH
strives to have one HSA for every 1000 people, but in
reality they often cater for much larger populations and
are usually over-burdened with many disease control
programs. In some areas in rural Malawi there are Vil-
lage Health committees, which are made up of voluntary
members of the community. They work hand in hand
with the HSA. We postulate that HSAs and where avail-
able village health volunteers (VHVs) are an option for
reminding mothers to give PMC to their child (Arm 3).
Another option for delivery of PMC is to request the
mother or caretaker to return to the health care facility
to collect the drugs for each treatment course (Arms 4
and 5). This is a plausible strategy as it is consistent with
the management of chronic illness such as TB and HIV
where drugs are routinely collected from a health facility
by the patients. This would be an alternative strategy as
part of EPI or management of other chronic illnesses e.g.
chest follow up clinic.
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